

Complete Summary

TITLE

Rhinitis: percentage of patients with seasonal allergic rhinitis prescribed prophylactic medication.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Rhinitis. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 May. 34 p. [86 references]

Measure Domain

PRIMARY MEASURE DOMAIN

Process

The validity of measures depends on how they are built. By examining the key building blocks of a measure, you can assess its validity for your purpose. For more information, visit the [Measure Validity](#) page.

SECONDARY MEASURE DOMAIN

Does not apply to this measure

Brief Abstract

DESCRIPTION

This measure is used to assess the percentage of patients with seasonal allergic rhinitis prescribed prophylactic medication.

RATIONALE

The priority aim addressed by this measure is to increase the use of prophylactic medications for patients with seasonal allergic rhinitis.

PRIMARY CLINICAL COMPONENT

Allergic rhinitis (seasonal symptoms); prophylactic medication (intranasal corticosteroids, antihistamines)

DENOMINATOR DESCRIPTION

Number of patients with a diagnosis of allergic rhinitis with seasonal symptoms (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

NUMERATOR DESCRIPTION

Number of patients with a prescription of intranasal corticosteroid or antihistamine and documentation of patient education to begin treatment 1 to 2 weeks prior to the anticipated start of symptoms (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

Evidence Supporting the Measure

EVIDENCE SUPPORTING THE CRITERION OF QUALITY

- A clinical practice guideline or other peer-reviewed synthesis of the clinical evidence

NATIONAL GUIDELINE CLEARINGHOUSE LINK

- [Rhinitis.](#)

Evidence Supporting Need for the Measure

NEED FOR THE MEASURE

Unspecified

State of Use of the Measure

STATE OF USE

Current routine use

CURRENT USE

Internal quality improvement

Application of Measure in its Current Use

CARE SETTING

Physician Group Practices/Clinics

PROFESSIONALS RESPONSIBLE FOR HEALTH CARE

Physicians

LOWEST LEVEL OF HEALTH CARE DELIVERY ADDRESSED

Group Clinical Practices

TARGET POPULATION AGE

Age 5 to 65 years

TARGET POPULATION GENDER

Either male or female

STRATIFICATION BY VULNERABLE POPULATIONS

Unspecified

Characteristics of the Primary Clinical Component

INCIDENCE/PREVALENCE

Unspecified

ASSOCIATION WITH VULNERABLE POPULATIONS

Unspecified

BURDEN OF ILLNESS

Unspecified

UTILIZATION

Unspecified

COSTS

Unspecified

Institute of Medicine National Healthcare Quality Report Categories

IOM CARE NEED

Living with Illness

IOM DOMAIN

Effectiveness

CASE FINDING

Users of care only

DESCRIPTION OF CASE FINDING

Patients age 5 to 65 with a diagnosis of allergic rhinitis with annually recurring symptoms

Identify patients diagnosed with allergic rhinitis using the specified diagnosis codes who presented during the months of April through October. Some medical groups will be able to identify the population of patients through patient computer records of International Classification of Diseases, Ninth Revision (ICD-9) codes.

The medical record of each patient is reviewed to determine if the rhinitis is seasonal. If the patient is determined to have seasonal allergic rhinitis, the medical record is checked for a prescription for an intranasal corticosteroid OR antihistamine AND if the patient was given instruction to begin treatment 1 to 2 weeks prior to the typical start of symptoms.

The suggested time period for data collection is a calendar month.

DENOMINATOR SAMPLING FRAME

Patients associated with provider

DENOMINATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of patients with a diagnosis of allergic rhinitis with seasonal symptoms as identified by the following International Classification of Diseases, Ninth Revision (ICD-9) code of 477.9 who presented during the months of April through October

Exclusions

Unspecified

DENOMINATOR (INDEX) EVENT

Clinical Condition

DENOMINATOR TIME WINDOW

Time window is a fixed period of time

NUMERATOR INCLUSIONS/EXCLUSIONS

Inclusions

Number of patients with a prescription of intranasal corticosteroid* or

antihistamine* * and documentation of patient education to begin treatment 1 to 2 weeks prior to the anticipated start of symptoms

*Corticosteroids:

- Nasonex
- Flonase
- Nasalide
- Nasacort aerosol
- Nasacort AQ
- Rhinocort AQ

**Antihistamines:

Nasal

- Azelastine

Oral

- Dimetane
- Chlor-Trimeton
- Tavist
- Periactin
- Benadryl
- Atarax
- Vistaril
- PBZ
- Zyrtec
- Claritin
- Allegra
- Clarinex
- Bromfed
- Bromfed PD
- Deconamine SR
- Kronofed
- Trinalin
- Zyrtec D
- Claritin D
- Allegra D

Exclusions
Unspecified

NUMERATOR TIME WINDOW

Encounter or point in time

DATA SOURCE

Administrative data
Medical record

LEVEL OF DETERMINATION OF QUALITY

Individual Case

PRE-EXISTING INSTRUMENT USED

Unspecified

Computation of the Measure

SCORING

Rate

INTERPRETATION OF SCORE

Better quality is associated with a higher score

ALLOWANCE FOR PATIENT FACTORS

Unspecified

STANDARD OF COMPARISON

Internal time comparison

Evaluation of Measure Properties

EXTENT OF MEASURE TESTING

Unspecified

Identifying Information

ORIGINAL TITLE

Percentage of patients with seasonal allergic rhinitis prescribed prophylactic medication.

MEASURE COLLECTION

[Rhinitis Measures](#)

DEVELOPER

Institute for Clinical Systems Improvement

ADAPTATION

Measure was not adapted from another source.

RELEASE DATE

2003 May

MEASURE STATUS

This is the current release of the measure.

SOURCE(S)

Institute for Clinical Systems Improvement (ICSI). Rhinitis. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2003 May. 34 p. [86 references]

MEASURE AVAILABILITY

The individual measure, "Percentage of patients with seasonal allergic rhinitis prescribed prophylactic medication," is published in "Health Care Guideline: Rhinitis." This document is available from the [Institute for Clinical Systems Improvement \(ICSI\) Web site](#).

For more information, contact ICSI at, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; phone: 952-814-7060; fax: 952-858-9675; Web site: www.icsi.org; e-mail: icsi.info@icsi.org.

NQMC STATUS

This NQMC summary was completed by ECRI on May 26, 2005.

COPYRIGHT STATEMENT

This NQMC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Measure) is based on the original measure, which is subject to the measure developer's copyright restrictions.

The abstracted ICSI Measures contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Measures are downloaded by an individual, the individual may not distribute copies to third parties.

If the abstracted ICSI Measures are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.

All other copyright rights in the abstracted ICSI Measures are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Measures.

© 2006 National Quality Measures Clearinghouse

Date Modified: 9/25/2006

The logo for FIRSTGOV, with "FIRST" in blue and "GOV" in red, and a small red star above the "I".

